

Robert L Findling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6058666/publications.pdf>

Version: 2024-02-01

179
papers

7,842
citations

44069

48
h-index

60623

81
g-index

203
all docs

203
docs citations

203
times ranked

5027
citing authors

#	ARTICLE	IF	CITATIONS
1	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 107-125.	0.5	442
2	Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. <i>Clinical Therapeutics</i> , 2007, 29, 450-463.	2.5	387
3	Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. <i>Bipolar Disorders</i> , 2001, 3, 202-210.	1.9	281
4	A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 1432-1441.	7.2	226
5	Human iPSC Glial Mouse Chimeras Reveal Glial Contributions to Schizophrenia. <i>Cell Stem Cell</i> , 2017, 21, 195-208.e6.	11.1	204
6	Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 948-957.e4.	0.5	196
7	Double-Blind 18-Month Trial of Lithium Versus Divalproex Maintenance Treatment in Pediatric Bipolar Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 409-417.	0.5	188
8	A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. <i>The Lancet Digital Health</i> , 2020, 2, e168-e178.	12.3	186
9	A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 280-288.	0.5	174
10	Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With Aripiprazole. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1441-1451.	2.2	159
11	Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQ. <i>American Journal of Psychiatry</i> , 2004, 161, 677-684.	7.2	154
12	The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. <i>Bipolar Disorders</i> , 2017, 19, 524-543.	1.9	152
13	Examining the Proposed Disruptive Mood Dysregulation Disorder Diagnosis in Children in the Longitudinal Assessment of Manic Symptoms Study. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1342-1350.	2.2	147
14	Developing a 10-Item Mania Scale From the Parent General Behavior Inventory for Children and Adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 831-839.	2.2	142
15	Discriminative validity of parent report of hypomanic and depressive symptoms on the General Behavior Inventory.. <i>Psychological Assessment</i> , 2001, 13, 267-276.	1.5	117
16	Venlafaxine ER for the Treatment of Pediatric Subjects With Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 479-488.	0.5	112
17	Characteristics of Children With Elevated Symptoms of Mania. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1664-1672.	2.2	111
18	Double-Blind, Placebo-Controlled Trial of Divalproex Monotherapy in the Treatment of Symptomatic Youth at High Risk for Developing Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 781-788.	2.2	104

#	ARTICLE	IF	CITATIONS
19	An update on pharmacotherapy of autism spectrum disorder in children and adolescents. <i>International Review of Psychiatry</i> , 2018, 30, 78-95.	2.8	103
20	Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2011, 50, 395-405.	0.5	101
21	Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 699-710.	1.3	100
22	Quetiapine in Nine Youths with Autistic Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 287-294.	1.3	91
23	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Demographic and Clinical Characteristics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 979-988.	0.5	91
24	Early symptoms of mania and the role of parental risk. <i>Bipolar Disorders</i> , 2005, 7, 623-634.	1.9	89
25	Methylphenidate in the Treatment of Children and Adolescents With Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 1445-1453.	0.5	87
26	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Methylphenidate Transdermal System in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 149-159.	2.2	84
27	Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. <i>CNS Spectrums</i> , 2008, 13, 614-620.	1.2	79
28	Methodological Issues and Controversies in Clinical Trials with Child and Adolescent Patients with Bipolar Disorder: Report of a Consensus Conference. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2003, 13, 13-27.	1.3	76
29	Longitudinal Assessment of Manic Symptoms (LAMS) Study. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1511-1517.	2.2	75
30	Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life. <i>Journal of Autism and Developmental Disorders</i> , 2019, 49, 3218-3230.	2.7	73
31	Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 252-261.e3.	0.5	72
32	The Workforce Shortage of Child and Adolescent Psychiatrists: Is It Time for a Different Approach?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 300-301.	0.5	71
33	Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 1153-1163.	2.7	70
34	Combination Lithium and Divalproex Sodium in Pediatric Bipolar Symptom Restabilization. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 142-148.	0.5	65
35	Efficacy and Safety of Extended-Release Quetiapine Fumarate in Youth with Bipolar Depression: An 8 Week, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 325-335.	1.3	65
36	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 969-978.	0.5	64

#	ARTICLE	IF	CITATIONS
37	Effectiveness, Safety, and Pharmacokinetics of Quetiapine in Aggressive Children With Conduct Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 792-800.	0.5	63
38	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.	1.9	62
39	Disruptive Mood Dysregulation Disorder in a Community Mental Health Clinic: Prevalence, Comorbidity and Correlates. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 123-130.	1.3	62
40	A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 19-33.	1.3	61
41	Decreased amygdala-insula resting state connectivity in behaviorally and emotionally dysregulated youth. <i>Psychiatry Research - Neuroimaging</i> , 2015, 231, 77-86.	1.8	61
42	The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 131-145.	1.3	60
43	A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. <i>Clinical Therapeutics</i> , 2020, 42, 1452-1466.	2.5	58
44	Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 57-63.	2.2	58
45	Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 327-342.	1.3	57
46	Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 441-446.	1.4	56
47	Post-Acute Effectiveness of Lithium in Pediatric Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 80-90.	1.3	52
48	An Open-Label Pilot Study of St. John's Wort in Juvenile Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 908-914.	0.5	50
49	Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 1032-1041.	0.5	50
50	A Prospective Study of Stimulant Response in Preschool Children: Insights From ROC Analyses. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2004, 43, 251-259.	0.5	49
51	Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 545-557.	1.3	48
52	Comparison of the clinical efficacy of twice-daily Ritalin® and once-daily Equasym®, XL with placebo in children with Attention Deficit/Hyperactivity Disorder. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 450-459.	4.7	46
53	A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release) Tj ETQq1 1 0,784314 rgBT /Ove	2.6	46
54	Parsing Dimensional vs Diagnostic Category-Related Patterns of Reward Circuitry Function in Behaviorally and Emotionally Dysregulated Youth in the Longitudinal Assessment of Manic Symptoms Study. <i>JAMA Psychiatry</i> , 2014, 71, 71.	11.0	45

#	ARTICLE	IF	CITATIONS
55	Maladaptive Aggression: With a Focus on Impulsive Aggression in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 576-591.	1.3	45
56	Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 195-205.	1.3	44
57	Predictors and moderators of agreement between clinical and research diagnoses for children and adolescents.. <i>Journal of Consulting and Clinical Psychology</i> , 2014, 82, 1151-1162.	2.0	44
58	Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive-Compulsive Disorder. <i>Neuropsychopharmacology</i> , 2006, 31, 1274-1285.	5.4	43
59	An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 431-439.	1.3	42
60	The 24-month course of manic symptoms in children. <i>Bipolar Disorders</i> , 2013, 15, 669-679.	1.9	42
61	Pharmacological Treatment of Depression in Children and Adolescents. <i>Paediatric Drugs</i> , 1999, 1, 161-182.	3.1	41
62	Effectiveness, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Optimization Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 649-662.	1.3	41
63	Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 395-402.	3.7	39
64	Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. <i>Clinical Therapeutics</i> , 2015, 37, 2788-2797.	2.5	37
65	Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 384-396.	1.3	36
66	Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2017, 56, 77-90.	3.5	36
67	Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. <i>Clinical Therapeutics</i> , 2009, 31, 1844-1855.	2.5	35
68	Paediatric uses of atypical antipsychotics. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 935-945.	1.8	34
69	A26-Week Open-Label Study of Quetiapine in Children with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 1-9.	1.3	33
70	Evidence-Based Assessment From Simple Clinical Judgments to Statistical Learning: Evaluating a Range of Options Using Pediatric Bipolar Disorder as a Diagnostic Challenge. <i>Clinical Psychological Science</i> , 2018, 6, 243-265.	4.0	33
71	First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 404-410.	1.4	32
72	White Matter Structure in Youth With Behavioral and Emotional Dysregulation Disorders. <i>JAMA Psychiatry</i> , 2015, 72, 367.	11.0	32

#	ARTICLE	IF	CITATIONS
73	Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent Signaling. <i>Cell Reports</i> , 2019, 27, 3832-3843.e6.	6.4	32
74	Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 287-296.e4.	0.5	32
75	Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. <i>Clinical Therapeutics</i> , 2021, 43, 684-700.	2.5	32
76	Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. <i>CNS Drugs</i> , 2021, 35, 643-653.	5.9	30
77	Guanfacine Extended Release Adjunctive to a Psychostimulant in the Treatment of Comorbid Oppositional Symptoms in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 245-252.	1.3	28
78	The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1589.	2.2	26
79	A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 370-380.	1.4	26
80	Use of antipsychotics in children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 7, 29-40.	2.2	26
81	Demographic and clinical correlates of autism symptom domains and autism spectrum diagnosis. <i>Autism</i> , 2014, 18, 571-582.	4.1	25
82	Disruptive Mood Dysregulation Disorder and Bipolar Disorder Not Otherwise Specified: Fraternal or Identical Twins?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 138-146.	1.3	25
83	Progress in diagnosis and treatment of bipolar disorder among children and adolescents: an international perspective. <i>Evidence-Based Mental Health</i> , 2018, 21, 177-181.	4.5	25
84	Venlafaxine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 433-445.	1.3	24
85	Clinical Significance of Treatment Effects with Aripiprazole versus Placebo in a Study of Manic or Mixed Episodes Associated with Pediatric Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 72-79.	1.3	24
86	Cognitive flexibility and performance in children and adolescents with threshold and sub-threshold bipolar disorder. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 625-638.	4.7	24
87	Clinical, cortical thickness and neural activity predictors of future affective lability in youth at risk for bipolar disorder: initial discovery and independent sample replication. <i>Molecular Psychiatry</i> , 2019, 24, 1856-1867.	7.9	24
88	A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 864-874.	1.3	23
89	Parenting Stress Among Caregivers of Children With Bipolar Spectrum Disorders. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2018, 47, S306-S320.	3.4	23
90	Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. <i>Paediatric Drugs</i> , 2016, 18, 367-378.	3.1	22

#	ARTICLE	IF	CITATIONS
91	Psychopharmacology of Bipolar Disorders in Children and Adolescents. <i>Pediatric Clinics of North America</i> , 2017, 64, 1209-1222.	1.8	22
92	Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 93-100.	2.4	21
93	Is There a Role for Clozapine in the Treatment of Children and Adolescents?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 423-428.	0.5	21
94	The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 52-65.	1.3	21
95	Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 4, 9-14.	2.2	21
96	An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 345-351.	1.3	20
97	Diagnostic efficiency of the CBCL thought problems and DSM-oriented psychotic symptoms scales for pediatric psychotic symptoms. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 1491-1498.	4.7	19
98	Atypical antipsychotics in the treatment of children and adolescents: clinical applications. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 6, 30-44.	2.2	19
99	Somatic treatment for depressive illnesses in children and adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2002, 11, 555-578.	1.9	18
100	Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 55-65.	1.3	18
101	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. <i>Journal of Affective Disorders</i> , 2020, 272, 508-520.	4.1	18
102	Suicide Risk Screening in Pediatric Outpatient Neurodevelopmental Disabilities Clinics. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2022, 43, 181-187.	1.1	18
103	A 6-Month, Open-Label, Extension Study of the Tolerability and Effectiveness of the Methylphenidate Transdermal System in Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 365-375.	1.3	17
104	A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder. <i>Paediatric Drugs</i> , 2018, 20, 353-363.	3.1	16
105	Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 183-210.	1.9	16
106	Diagnostic Trends and Prescription Patterns in Disruptive Mood Dysregulation Disorder and Bipolar Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 434-445.	0.5	16
107	Narrative Review: Impairing Emotional Outbursts: What They Are and What We Should Do About Them. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 135-150.	0.5	16
108	Unfiltered Administration of the YMRS and CDRS-R in a Clinical Sample of Children. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2015, 44, 992-1007.	3.4	15

#	ARTICLE	IF	CITATIONS
109	Safety considerations in the psychopharmacology of pediatric bipolar disorder. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 777-794.	2.4	15
110	Developing and Validating Short Forms of the Parent General Behavior Inventory Mania and Depression Scales for Rating Youth Mood Symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 49, 162-177.	3.4	15
111	Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 10, 26-31.	2.2	14
112	Diagnostic validity and reliability of a Korean version of the Parent and Adolescent General Behavior Inventories. <i>Comprehensive Psychiatry</i> , 2014, 55, 1730-1737.	3.1	13
113	Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 526-534.	1.3	13
114	Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 1026-1033.	0.5	13
115	Comparing the Diagnostic Accuracy of Five Instruments for Detecting Posttraumatic Stress Disorder in Youth. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2017, 46, 511-522.	3.4	12
116	A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 47-54.	1.3	12
117	A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.0	12
118	Pharmacotherapy of Aggression in a 9-Year-Old With ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 653-658.	0.5	11
119	Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 90-99.	1.3	11
120	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.	1.2	11
121	A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 355-365.	1.3	11
122	Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2767.	4.3	10
123	Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 439-447.	1.3	10
124	Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 166-172.	1.3	10
125	Positive Emotion Specificity and Mood Symptoms in an Adolescent Outpatient Sample. <i>Cognitive Therapy and Research</i> , 2017, 41, 393-405.	1.9	9
126	Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. <i>Paediatric Drugs</i> , 2018, 20, 121-134.	3.1	9

#	ARTICLE	IF	CITATIONS
127	Development of bipolar disorder and other comorbidity among youth with attention-deficit/hyperactivity disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2020, 61, 175-181.	5.2	9
128	Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 546-557.	3.9	8
129	Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 117-124.	1.3	8
130	Asenapine pharmacokinetics and tolerability in a pediatric population. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2677-2693.	4.3	8
131	A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression. <i>Postgraduate Medicine</i> , 2019, 131, 129-137.	2.0	8
132	Developing and Validating a Definition of Impulsive/Reactive Aggression in Youth. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 49, 787-803.	3.4	8
133	Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 128-136.	1.3	8
134	Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 1106-1118.e2.	0.5	8
135	Update on the treatment of bipolar disorder in children and adolescents. <i>European Psychiatry</i> , 2005, 20, 87-91.	0.2	7
136	Development of Alcohol and Drug Use in Youth With Manic Symptoms. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 149-156.	0.5	7
137	Comparing the CASI-4R and the PGBI-10ÅM for Differentiating Bipolar Spectrum Disorders from Other Outpatient Diagnoses in Youth. <i>Journal of Abnormal Child Psychology</i> , 2017, 45, 611-623.	3.5	7
138	Diagnostic Efficiency of the Child and Adolescent Symptom Inventory (CASI-4R) Depression Subscale for Identifying Youth Mood Disorders. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2018, 47, 832-846.	3.4	7
139	Generalizing the Prediction of Bipolar Disorder Onset Across High-Risk Populations. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 1010-1019.e2.	0.5	7
140	Evaluating and Validating GBI Mania and Depression Short Forms for Self-Report of Mood Symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 50, 1-17.	3.4	7
141	Subtle Motor Signs as a Biomarker for Mindful Movement Intervention in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2020, 41, 349-358.	1.1	7
142	Changes in Emotions Related to Medication Used to Treat ADHD. Part II: Clinical Approaches. <i>Journal of Attention Disorders</i> , 2011, 15, 113-121.	2.6	6
143	Decreased functional connectivity in the fronto-parietal network in children with mood disorders compared to children with dyslexia during rest: An fMRI study. <i>NeuroImage: Clinical</i> , 2018, 18, 582-590.	2.7	6
144	Psychiatric Diseases in Children and Adolescents. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 397-413.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Developing Empirical Latent Profiles of Impulsive Aggression and Mood in Youths across Three Outpatient Samples. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2023, 52, 196-211.	3.4	6
146	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.	2.2	6
147	Diagnosis and Treatment of Bipolar Disorder in Young Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e45.	2.2	6
148	Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 1423-1434.	0.5	6
149	Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1941-1952.	2.2	5
150	Use of quetiapine in children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 13, 27-31.	2.2	5
151	Physical Activity Levels and Screen Time among Youth with Overweight/Obesity Using Mental Health Services. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2261.	2.6	5
152	Somatic treatment for depressive illnesses in children and adolescents. <i>Psychiatric Clinics of North America</i> , 2004, 27, 113-137.	1.3	4
153	A Novel Assessment Tool for Impulsive Aggression in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 592-598.	1.3	4
154	Irritability Is Associated with Illness Severity and Anhedonia Is Associated with Functional Impairment Among Depressed Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 531-537.	1.3	4
155	Reading related white matter structures in adolescents are influenced more by dysregulation of emotion than behavior. <i>NeuroImage: Clinical</i> , 2017, 15, 732-740.	2.7	3
156	Factors Influencing Emerging Adults'™ Use of Outpatient Mental Health Services. <i>Evidence-Based Practice in Child and Adolescent Mental Health</i> , 2019, 4, 113-121.	1.0	3
157	Application of the Impulsive Aggression Diary in Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 599-607.	1.3	3
158	Hopelessness and depressive symptoms in children and adolescents: An integrative data analysis.. <i>Journal of Abnormal Psychology</i> , 2021, 130, 594-607.	1.9	3
159	Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 143-152.	1.3	3
160	Hemoglobin and the brain: a piece of the autism puzzle?. <i>Journal of Autism and Developmental Disorders</i> , 1998, 28, 579-582.	2.7	2
161	Improving Clinical Prediction of Bipolar Spectrum Disorders in Youth. <i>Journal of Clinical Medicine</i> , 2014, 3, 218-232.	2.4	2
162	Diagnostic Accuracy of the CASI-4R Psychosis Subscale for Children Evaluated in Pediatric Outpatient Clinics. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2019, 48, 610-621.	3.4	2

#	ARTICLE	IF	CITATIONS
163	Iâ€™m Not Being Critical, Youâ€™re Just Too Sensitive: Pediatric Bipolar Disorder and Families. Journal of Psychopathology and Behavioral Assessment, 2021, 43, 84-94.	1.2	2
164	Management of the COVID-19-Infected Psychiatric Inpatients: Unique Infection Prevention Considerations and Evolving Strategies. Current Treatment Options in Infectious Diseases, 2021, 13, 165-174.	1.9	2
165	Diagnostic accuracy of Achenbach scales in detecting youthsâ€™ substance use disorders.. Psychological Assessment, 2022, 34, 570-582.	1.5	2
166	Additional considerations beyond efficacy for lithium in pediatric bipolar disorder. Bipolar Disorders, 2019, 21, 558-559.	1.9	1
167	Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents. CNS Spectrums, 2020, 26, 1-9.	1.2	1
168	Predictors of Hospitalization in a Cohort of Children with Elevated Symptoms of Mania. Administration and Policy in Mental Health and Mental Health Services Research, 2021, 48, 171-180.	2.1	1
169	Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disorders, 2001, 3, 202.	1.9	1
170	Diagnosing and Managing Complicated ADHD. Journal of Clinical Psychiatry, 2007, 68, 1963-1970.	2.2	1
171	Little Agreement on Treating Residual Bipolar Disorder Symptoms in a Child. primary care companion for CNS disorders, The, 2020, 22, .	0.6	1
172	Atypical antipsychotics in the treatment of children and adolescents. Journal of Clinical Psychiatry, 2004, 65 Suppl 6, 3-4.	2.2	1
173	Using machine learning and surface reconstruction to accurately differentiate different trajectories of mood and energy dysregulation in youth. PLoS ONE, 2017, 12, e0180221.	2.5	0
174	Drs. Stepanova and Findling Reply. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 978-979.	0.5	0
175	Associations between Parental Psychopathology and Sexual Behavior in an Outpatient Psychiatric Sample. Journal of Clinical Child and Adolescent Psychology, 2020, 49, 50-59.	3.4	0
176	Affective Processing Biases in Relation to Past, Current, and Future Depression in Children and Adolescents. Journal of Affective Disorders, 2020, 273, 146-156.	4.1	0
177	Preliminary evaluation of the utility of parental ratings in a Child Network. Psychiatry Research, 2020, 290, 112908.	3.3	0
178	Diagnosis and Pharmacotherapy of Bipolar Depression in Pediatric Patients. Journal of Clinical Psychiatry, 2021, 82, .	2.2	0
179	Individualizing Treatment Selection for Pediatric and Adult Patients With Bipolar Depression. Journal of Clinical Psychiatry, 2021, 82, .	2.2	0